30-day average of 22 articles · scale −100 to +100
Across 22 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of Intuitive Surgical news is Somewhat Bullish (+37)
on a scale from −100 to +100.
That is down 7 points from the previous 30 days (+44).
🌍 Worldwide procedures grew 14%, with international markets up 20%.
📉 U.S. da Vinci procedure growth slowed to 10% in Q3.
Slightly Bullish +20
A $5.9 Billion Fund Is Betting Big on Intuitive Surgical
AI-generated analysis
Key insights
📉 Intuitive Surgical's U.S. da Vinci procedure growth slowed to 10% in Q3, the lowest level since the COVID-19 pandemic.
📈 Worldwide da Vinci procedures grew 14% in Q3, with international markets expanding at a robust 20% rate.
💰 The company placed 546 da Vinci systems in the third quarter, up from 427 placements a year earlier.
✂️ Intuitive plans to reduce instrument and accessory revenue per procedure by 3% to 5% to win high-volume benign surgeries.
📉 Valuation compression has pushed the stock to 37x forward earnings, down from a five-year average of 54x.
📉 The consensus analyst price target fell from $593 to $487 following recent operational and financial data.
💼 GuardCap Asset Management opened a new position in ISRG with 167,863 shares worth $68 million in Q3.
🔭 Analysts expect normalized EPS to grow from $8.93 in 2025 to $14.04 by 2028.
📅 The next major catalyst is the fourth-quarter report expected early next year regarding U.S. growth trends.
📈 Bullish signals
📉Intuitive Surgical achieved a 22% revenue increase and 14% worldwide procedure growth in Q3, driven by strong international expansion.
💰The company successfully placed 546 da Vinci systems in the third quarter, demonstrating continued hospital adoption despite domestic headwinds.
🔭Analysts project normalized earnings per share to rise significantly from $8.93 in 2025 to $14.04 by 2028.
📉 Risk factors
📉U.S. da Vinci procedure growth slowed to 10% in Q3, the lowest rate seen since the COVID-19 pandemic.
✂️The company plans to cut instrument and accessory revenue per procedure by 3% to 5%, which will temporarily reduce revenue per case before volume gains materialize.
📉Valuation compression has driven the stock price down to 37x forward earnings, well below its five-year average of 54x.
Article
Intuitive Surgical (ISRG) recently faced headwinds as U.S. da Vinci procedure growth slowed to 10% in the third quarter, marking its lowest rate since the COVID-19 pandemic. Despite this domestic slowdown, the company reported a 22% revenue increase and 14% worldwide procedure growth, driven by strong international expansion with 20% growth outside the U.S. Additionally, Intuitive successfully placed 546 da Vinci systems in the third quarter, an increase from 427 a year prior.
To capture more high-volume benign surgeries, Intuitive Surgical plans to cut instrument and accessory revenue per procedure by 3% to 5%. This strategic pricing adjustment has caused the stock to trade at 37x forward earnings, significantly below its five-year average of 54x. Consequently, the consensus analyst price target has decreased from $593 a year ago to $487, though this still implies potential upside from recent lows.
GuardCap Asset Management, which oversees $5.9 billion in assets, initiated a new position in Intuitive Surgical during the third quarter, purchasing 167,863 shares worth approximately $68 million. This investment represents 4.7% of GuardCap's U.S. stock holdings and is its largest new or added position for the period. Analysts project normalized earnings per share to rise from $8.93 in 2025 to $14.04 by 2028, suggesting long-term growth potential despite current valuation compression.
The company's next critical test will be its fourth-quarter report early next year, which is expected to provide clarity on U.S. procedure growth trends for 2027. Investors are closely watching whether the domestic slowdown persists or if international momentum can offset any further declines in the core U.S. market.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Intuitive Surgical (NASDAQ: ISRG) stock is currently trading near its 52-week lows, having declined approximately 30% from its early 2025 highs. Despite this drawdown, Wall Street analysts maintain an upbeat outlook with an average price target of $570, suggesting a potential recovery and gain of over 30% from current depressed levels. The article notes that while the company's P/E ratio is lofty at 51x, it has decreased from a five-year average of 70x.
The company operates as an industry leader in surgical robotics with its da Vinci system, which had 11,395 units installed worldwide by the end of Q1 2026, representing a 12% year-over-year increase. Demand for the technology is robust, evidenced by a 17% rise in the number of surgeries performed annually. Crucially, Intuitive Surgical's revenue model relies heavily on annuity-like income streams from instruments, accessories, and services, which constitute roughly 75% of its top line.
Historical data suggests that significant drawdowns are common for the stock, with the company recovering and pushing higher after similar declines in the past. Analysts believe that even a temporary slowdown in new system sales would not derail long-term prospects due to the recurring revenue nature of their business model. The article advises investors to view Intuitive Surgical as a long-term hold rather than a short-term trade, noting its decade-long opportunity in healthcare technology.
📉 ISRG stock down ~30% near 52-week lows.
🎯 Analysts target $570, implying >30% upside.
🤖 da Vinci installations hit 11,395 globally in Q1 2026.
💰 Instruments and services drive ~75% of revenue.
📈 Surgeries using da Vinci robots rose 17%.
📉 ISRG stock is down ~30% from early 2025 highs and trading near 52-week lows.
🎯 Wall Street analysts set an average price target of $570, implying a >30% upside from current levels.
🤖 The da Vinci surgical system reached 11,395 global installations by Q1 2026, up 12% year-over-year.
📈 Surgeries performed using da Vinci robots increased 17% year over year.
💰 Instruments, accessories, and services generate ~75% of revenue as annuity-like income streams.
📉 P/E ratio is currently 51x, down from a five-year average of 70x.
🕰️ Historical data shows the stock has recovered from similar magnitude drawdowns multiple times since IPO.
🛡️ Recurring revenue model provides resilience against temporary slowdowns in new system sales.
📅 Analysts recommend a long-term hold strategy rather than short-term trading.
🚀 The company is positioned to benefit from expanding use cases and increased patient demand.
Bullish Signals
Analysts project $570 price target, >30% recovery from lows.
da Vinci installed base grew 12% YoY to 11,395 units.
Surgery volume rose 17% YoY, signaling strong market demand.
~75% revenue from recurring instrument and service sales.
Risk Factors
High P/E ratio of 51x may deter value investors.
No dividend payments make it unsuitable for income portfolios.
Stock could fall further before recovering from depressed levels.
Excluded from Motley Fool's top 10 immediate purchase list.
Bullish Signals
Analysts project a price target of $570, indicating a potential recovery of over 30% from current lows.
The da Vinci system installed base grew 12% year-over-year to 11,395 units globally by Q1 2026.
Surgery volume using the robotic system rose 17% year-over-year, signaling strong market demand.
Approximately 75% of revenue comes from recurring instrument and service sales rather than one-time hardware.
The company has successfully navigated multiple significant drawdowns historically, suggesting resilience.
Long-term growth drivers include expanding use cases for the robot and increasing patient demand.
Risk Factors
The stock trades at a high P/E ratio of 51x, which may deter value-oriented investors.
The company does not pay a dividend, making it unsuitable for income-focused portfolios.
There is a risk that the stock could fall further before recovering from current depressed levels.
Intuitive Surgical was excluded from The Motley Fool's top 10 stocks list for immediate purchase.
Intuitive Surgical (NASDAQ: ISRG) has announced a leadership change within its executive team, promoting Taylor Patton to the newly created role of Chief Commercial and Marketing Officer. Effective July 1, 2026, Patton will join the Executive Leadership Team, succeeding Henry Charlton in his previous title and assuming Charlton's new designation as Senior Vice President of Global Business Operations. This strategic move aims to leverage Patton's nearly two-decade tenure at the company, during which he served as Global Senior Vice President of Intuitive's endoluminal business. His promotion is specifically designed to capitalize on his deep experience across the da Vinci, Ion, and Digital platforms to maximize opportunities for consistent customer support and scale commercial operations in line with continued global growth.
Taylor Patton was praised by CEO Dave Rosa for building and scaling teams across multiple business units and geographies, demonstrating a proven ability to launch new technologies and establish trust with customers worldwide. In his new capacity, Patton will focus on expanding Intuitive's impact while ensuring world-class support for physicians and healthcare systems regardless of geography. Concurrently, Henry Charlton has expressed gratitude for his contributions to establishing Intuitive as a global healthcare leader, noting that he will now focus more specifically on generating value for patients, physicians, and healthcare systems globally. The company highlights the successful launch of the Ion platform under Patton's previous leadership as a key initiative involving complex multi-geography operations and differentiated technology introduction.
👋 Taylor Patton promoted to Chief Commercial and Marketing Officer effective July 2026.
🔄 Henry Charlton moves to Senior Vice President of Global Business Operations.
🚀 Patton will scale operations across da Vinci, Ion, and Digital platforms for growth.
👋 Intuitive Surgical announced the promotion of Taylor Patton to Chief Commercial and Marketing Officer (CCMO), effective July 1, 2026.
🔄 Patton will succeed Henry Charlton as CCMO, while Charlton transitions to Senior Vice President of Global Business Operations.
🤝 Both executives stated they will work closely together to ensure a smooth transition and advance the company's global impact.
💼 Patton brings nearly two decades of experience at Intuitive, having led teams across multiple business units and geographies.
🚀 The new CCMO will leverage his deep expertise in da Vinci, Ion, and Digital platforms to scale commercial operations for continued growth.
🌍 Patton previously served as Global Senior Vice President of the endoluminal business, leading the worldwide launch of the Ion platform.
💬 CEO Dave Rosa praised Patton's unique ability to launch new technologies and build commercial organizations globally.
🏥 Intuitive's executive team highlighted its goal to support over 20 million patients served by physicians using their minimally invasive care solutions.
🎯 The leadership team is focused on helping customers deliver differentiated outcomes, reduce total cost to treat, and achieve the Quintuple Aim.
📅 Taylor Patton has been with Intuitive since 2003 and expressed excitement about contributing to the company's next chapter in healthcare transformation.
🏢 Intuitive Surgical (NASDAQ: ISRG) is headquartered in Sunnyvale, California, and remains a global leader in robotic-assisted surgery.
Bullish Signals
Taylor Patton promoted to Chief Commercial and Marketing Officer effective July 1.
Patton brings two decades of experience across da Vinci, Ion, and Digital platforms.
Appointment highlights strong internal talent pool and organizational stability at Intuitive Surgical.
Legacy includes serving over 20 million patients globally as a robotic surgery pioneer.
Intuitive Surgical announced the promotion of Taylor Patton to Chief Commercial and Marketing Officer, effective July 1, adding a seasoned leader with nearly two decades of company experience to its Executive Leadership team.
Patton possesses deep expertise across Intuitive's da Vinci, Ion, and Digital platforms, positioning him to maximize opportunities for consistent customer support while scaling commercial operations for continued global growth.
The appointment highlights the strong internal talent pool and organizational stability at Intuitive Surgical, as Patton will build on the exceptional foundation established by outgoing leadership.
Intuitive's legacy is underscored by its long-term track record of serving over 20 million patients globally while establishing itself as a pioneer in minimally invasive care and robotic surgery.
Risk Factors
The article contains conflicting analyst signals that could indicate market skepticism; specifically, Goldman Sachs has lowered its price target on Intuitive Surgical (ISRG) from $621 to $558 within a short three-day window.
Intuitive Surgical (ISRG), Medtronic (MDT), and Stryker (SYK) are identified as key players where surgical robotics integrates with artificial intelligence capabilities. Intuitive Surgical reported Q1 FY26 non-GAAP EPS of $2.50, beating estimates by 18.66%, with revenue reaching $2.77 billion. The company's installed base of da Vinci systems (11,395 units) and Ion systems continues to expand, providing data for analytics platforms. While tariff headwinds from Mexico, Germany, and China impact margins by approximately 1.0%, the company maintains strong cash reserves and guidance suggests continued growth in procedure volumes for both its core da Vinci line and newer Ion system.
Medtronic achieved a significant milestone with FDA clearance for the Hugo robotic-assisted surgery system, enabling first cases in February 2026. Its Q3 FY26 revenue of $9.017 billion exceeded analyst expectations, driven notably by an 80% increase in overall Pulmonary Field Ablation solutions revenue. The company also expanded its portfolio with FDA clearance for the Stealth AXiS Surgical System for spinal procedures and a CE Mark for the Sphere-360 mapping catheter. Despite a non-GAAP gross margin slip to 64.9% due to $185 million in tariff headwinds, CEO Geoff Martha highlighted strong organic revenue growth of 6%, with shares trading at an attractive forward P/E of 14x despite a significant year-to-date drawdown.
Stryker faced a mixed quarter where Q1 FY26 adjusted EPS of $2.60 and revenue of $6.02 billion both missed consensus estimates due to $118 million in structural optimization charges linked to a March 11, 2026 cybersecurity incident. Operating margins were compressed to 21.1% from the prior year's 22.9%. However, the company maintains its full-year guidance for organic sales growth of 8.0% to 9.5% and adjusted EPS between $14.90 and $15.10. Growth in Mako-tethered orthopedic categories remains steady with knees growing 4.7% and hips growing 3.7%. Collectively, these three companies represent exposure to the AI-driven surgical robotics flywheel with durable moats built on installed bases, though their current market valuations reflect concerns regarding tariffs, cybersecurity events, and temporary margin pressures rather than a lack of fundamental strength.
🏥 Top robotics firms (Intuitive, Medtronic, Stryker) offer AI surgical exposure below 2026 highs.
⚠️ Stryker missed earnings due to a cyber incident causing margin compression and revenue misses.
💊 Medtronic beat estimates driven by Hugo system adoption despite facing significant tariff headwinds.
🤖 Intuitive Surgical continues strong performance with AI-ready installations and substantial cash pile growth.
📈 Surgical robotics is emerging as an AI-driven sector with major moats built on data flywheels from trained surgeons.
💼 The top three companies leading this transformation are Intuitive Surgical, Medtronic, and Stryker.
🚀 All three major players are currently trading below their 2026 highs, making the investment thesis more attractive now.
💵 Stryker reported Q1 FY26 adjusted EPS of $2.60, which missed the consensus estimate of $2.98.
⚠️ Stryker's revenue came in at $6.02 billion, falling short of the $6.33 billion expected by analysts.
🛡️ CEO Kevin Lobo cited a March 11, 2026 cybersecurity incident that contributed to margin compression from 22.9% to 21.1%.
🧠 Stryker's Mako robotic franchise is integrated with power tools and accessories under its new Ortho Tech business unit.
📉 Shares of Stryker have declined by 21.3% over the past year despite maintaining full-year growth guidance.
💊 Medtronic recently received FDA clearance for its Hugo robotic-assisted surgery system, with first cases completed in February 2026.
❤️ Cardiac Ablation Solutions at Medtronic showed exceptional growth, up 80% overall due to pulsed field ablation technology.
🦴 Medtronic also secured CE Mark approval for AI-adjacent mapping navigation systems used in spinal procedures and cardiac care.
📊 Medtronic posted Q3 FY26 revenue of $9.017 billion, beating estimates with 6% organic growth driven by the Hugo system.
🧨 Non-GAAP gross margin slipped to 64.9% due to a $185 million tariff headwind affecting FY26 guidance.
💰 Intuitive Surgical reported Q1 FY26 non-GAAP EPS of $2.50, beating estimates by 18.66% for the fourth consecutive quarter.
🤖 Intuitive's installed base grew to 11,395 da Vinci systems and 1,041 Ion systems, both feeding data back into digital platforms.
⚡ 232 of the new da Vinci placements were the AI-ready da Vinci 5 units, contributing to a 16% increase in procedures.
💵 Intuitive Surgical added $7.98 billion in cash after repurchasing 2.3 million shares for $1.1 billion.
🌍 The company faces a 1.0% margin headwind from tariffs across Mexico, Germany, and China but still grew operating income by 47.95%.
📉 Intuitive Surgical shares are down 24.3% year-to-date as institutional patience is tested despite strong earnings.
🧩 Collectively, these three companies offer exposure to AI in the operating room without the high multiples of pure software stocks.
Bullish Signals
Intuitive Surgical beat EPS estimates by 18.66% with Q1 FY26 non-GAAP EPS of $2.50.
Revenue jumped 22.96% YoY to $2.77B, driven by $1.69B high-margin Instruments & Accessories.
Installed base rose 12% for da Vinci systems and 22% for Ion platforms.
Ion system procedure volume surged 39% while operating income increased 47.95%.
Company holds robust $7.98B cash after repurchasing 2.3 million shares.
FY26 guidance projects 13.5% to 15.5% da Vinci procedure growth.
Medtronic beat with Q3 FY26 revenue of $9.017B and EPS of $1.36.
Risk Factors
Missed Q1 FY26 EPS estimates and revenue expectations.
Cybersecurity incident and $118M charges compressed operating margins.
Tariff exposure in Mexico, Germany, China creates margin headwinds.
Shares down 24.3% YTD stressing institutional patience.
AI-enabled data flywheel thesis treated as immaterial.
Mako revenue bundling prevents isolating AI growth.
Bullish Signals
Intuitive Surgical reported fourth consecutive EPS beats with Q1 FY26 non-GAAP EPS of $2.50 surpassing the $2.11 estimate by 18.66%.
Revenue grew 22.96% year over year to $2.77 billion, primarily driven by $1.69 billion in high-margin Instruments & Accessories.
The installed base expanded with 11,395 da Vinci systems (up 12%) and 1,041 Ion systems (up 22%), feeding a data flywheel for surgeon analytics.
Adoption of new platforms accelerated significantly, with 232 da Vinci 5 units placed in the quarter versus 431 total da Vinci placements.
Procedure volume surged 16% for da Vinci and an impressive 39% for the Ion system, while operating income jumped 47.95%.
The company holds a robust $7.98 billion in cash reserves after repurchasing 2.3 million shares for $1.1 billion.
FY26 guidance projects strong demand with 13.5% to 15.5% da Vinci procedure growth, reflecting market confidence despite temporary tariff headwinds.
Medtronic beat expectations with Q3 FY26 revenue of $9.017 billion and non-GAAP EPS of $1.36 surpassing the consensus.
Cardiac Ablation Solutions demonstrated explosive growth, driving revenue up 80% overall and 137% in the United States via pulsed field ablation.
Medtronic secured regulatory milestones including FDA clearance for the Hugo system with first cases completed in February 2026, and CE Mark for Sphere-360 mapping catheter.
CEO Geoff Martha highlighted strong organic revenue growth of 6% in Q3, which exceeded guidance and signaled an exciting expansion phase.
Despite sector drawdowns, Medtronic's forward P/E of 14x and analyst target of $108 present the stock as attractively priced.
Stryker CEO Kevin Lobo expressed confidence in recovering quickly from the March 11, 2026 cybersecurity incident while maintaining full-year guidance.
Key growth categories remain intact at Stryker with knees growing 4.7% and hips growing 3.7% under their Mako robotic platforms.
Stryker committed to sustained organic sales growth of 8.0% to 9.5% and adjusted EPS between $14.90 to $15.10 for the full year.
Risk Factors
Stryker missed Q1 FY26 adjusted EPS estimates ($2.60 vs $2.98) and revenue expectations ($6.02B vs $6.33B).
Stryker's adjusted operating margin compressed to 21.1% from 22.9% due to a March 11, 2026 cybersecurity incident and $118 million in structural optimization charges.
Intuitive Surgical faces tariff exposure across Mexico, Germany, and China embedded as a 1.0% margin headwind.
Medtronic is dealing with a $185 million tariff headwind that is baked into FY26 guidance.
Medtronic's non-GAAP gross margin slipped to 64.9% from 66.6%, indicating potential profitability pressure.
Intuitive Surgical's shares are down 24.3% year to date, putting institutional patience under stress despite insider accumulation.
The market currently treats the AI-enabled data flywheel thesis for surgical robotics as immaterial.
Stryker faces execution risk where Mako revenue is bundled, preventing investors from isolating the growth of their AI orthopedics flywheel.
Intuitive Surgical, Inc. (ISRG) is highlighted by Zacks Investment Research as a top growth stock candidate based on its proprietary scoring system which evaluates real growth prospects beyond traditional attributes. The report specifically assigns Intuitive Surgical a Growth Score of B and a Zacks Rank #2 (Buy), primarily due to favorable earnings history and recent positive trends in analyst estimate revisions. The analysis emphasizes that stocks with strong growth scores combined with Strong Buy (#1) or Buy (#2) ranks have historically outperformed the market, citing Intuitive Surgical's current metrics as key indicators of its potential for capital appreciation.
The primary driver for this recommendation is the company's projected earnings growth, which is expected to reach 16.5% for the current year. This projection significantly surpasses the industry average expectation of 12.3%, and aligns with Intuitive Surgical's historical EPS growth rate of 14.3%. Beyond just profit margins, the article notes that cash flow growth is a critical metric for expanding businesses without relying on expensive external capital. For Intuitive Surgical, year-over-year cash flow growth is currently at 15.8%, standing in stark contrast to the industry average of 0%.
The financial strength of the company is further illustrated by its long-term performance over the past 3-5 years, where it has achieved an annualized cash flow growth rate of 19.5% compared to the sector's 7.5% average. Additionally, the article points to a positive trend in earnings estimate revisions as another supporting factor; the Zacks Consensus Estimate for the current year has increased by 5.1% over the past month. These combined factors have secured Intuitive Surgical a top-tier status within the Zacks Style Scores system, positioning it as a solid choice for investors seeking growth and potential outperformance.
💰 ISRG boasts 16.5% projected EPS growth, significantly beating the industry average.
🚀 With a Zacks Rank #2 and Growth Score B, it qualifies as a strong buy.
Growth stocks carry above-average risk and volatility.
Intuitive Surgical (ISRG) faces significant loss risk if story ends.
Zacks Rank #2 is weaker than Strong Buy (#1).
Double-digit earnings growth for ISRG is preferable but not guaranteed.
Bullish Signals
Intuitive Surgical has earned a favorable Growth Score of B, supported by exceptionally surging profit levels that indicate strong prospects.
The company is expected to grow EPS by 16.5% this year, which significantly crushes the industry average of 12.3%.
Year-over-year cash flow growth for Intuitive Surgical is 15.8%, whereas the industry average stands at 0%, highlighting superior financial health.
The company's annualized cash flow growth rate has been 19.5% over the past 3-5 years compared to an industry average of 7.5%.
There have been upward revisions in current-year earnings estimates for Intuitive Surgical, with the Zacks Consensus Estimate surging 5.1% over the past month.
Intuitive Surgical carries a top Zacks Rank #2 (Buy), positioning the stock well for outperformance and attracting growth investors.
Risk Factors
The article explicitly states that growth stocks "usually carry above-average risk and volatility," warning investors of potential instability.
There is a significant risk if the growth story is found to be over or nearing its end, which could lead to "significant loss" for investors betting on Intuitive Surgical (ISRG).
The Zacks Rank of #2 (Buy) suggests the stock may not possess the strongest buy signals compared to stocks with a #1 (Strong Buy) ranking.
While the industry average EPS growth is cited as 12.3%, the article notes that double-digit earnings growth is only "preferable" rather than guaranteed for all growth investors, indicating room for potential underperformance relative to broader market expectations.
Intuitive Surgical (ISRG) is experiencing a period of valuation reassessment following a choppy recent stock price performance, with the share currently trading around $457.78. This marks a year-to-date decline of 18.54%, contrasting sharply with strong longer-term returns including a 51.04% three-year total shareholder return and a 64.51% five-year gain. The core investment thesis highlights the company's growing installed base of da Vinci surgical systems, which now totals 9,539 units globally, growing at an annual rate of 15.1%, and performs approximately 2.2 million procedures annually with procedure volume growing 22.2% per year.
A valuation model suggests a fair value price target of $532.46, implying the stock is currently trading at a 14% discount or modestly undervalued despite carrying an expensive multiple. The company trades at a Price-to-Earnings ratio of 54.4x, which is significantly higher than the 23.6x for the broader US Medical Equipment industry and 26.1x for direct peers, indicating investors are paying a substantial premium for its earnings growth prospects. While the strong recurring revenue from established installed bases supports long-term value, the high valuation multiple creates sensitivity to potential slowdowns in procedure volumes or delays in hospital capital spending. The analysis concludes that sentiment is split between short-term weakness and long-term integrity, with key rewards tied to the expanding surgical robotics business needing careful monitoring against market expectations.
📉 Stock down 18.54% YTD despite fair value peg of $532.46.
🤖 Installed base growing at 15.1% with procedure volume up 22.2%.
💰 Trades at 54.4x P/E, double the sector average due to recurring revenue.
⚠️ High valuation exposes stock to earnings misses and hospital spending delays.
📉 Intuitive Surgical (ISRG) has faced recent share price weakness with a 18.54% decline year-to-date and a 2.8% drop over the last week.
💹 The stock currently trades at $457.78, though Tokyo's analysis pegs its fair value at $532.46, suggesting it is modestly undervalued.
🤖 A global installed base of 9,539 da Vinci systems continues to grow annually at a rate of 15.1%.
📈 These systems are performing approximately 2.2 million procedures per year, with procedure volume growth accelerating at 22.2% annually.
💰 Intuitive Surgical trades at a P/E multiple of 54.4x, which is double that of the broader US medical equipment sector average of 23.6x.
⚖️ The high valuation premium implies significant sensitivity to any changes in earnings expectations or growth assumptions.
📉 Investors are reassessing whether current prices reflect a fresh entry point or if future growth has already been fully priced in by the market.
🏥 Risks to the long-term narrative include potential slowdowns in procedure volumes or delays in hospital spending on new and existing systems.
💼 The company's recurring revenue model from installed da Vinci systems is considered a key differentiator driving its valuation.
📊 Simply Wall St recommends diversifying into other robotics, automation, and high-quality stocks to mitigate concentration risk.
⚠️ The article includes a disclaimer that the analysis uses historical data and analyst forecasts but does not constitute financial advice.
Bullish Signals
3-year TSR: 51.04%; 5-year TSR: 64.51%.
Installed base grows 15.1% annually.
Procedure volume up 22.2% to 2.2M.
Fair value $532.46 vs price $457.78.
Steady revenue and net income growth.
Risk Factors
Stock fell 18.54% year-to-date with a 2.8% weekly drop.
Rich 54.4x P/E multiple exposes stock to peer average of 23.6x.
Growth hinges on procedure volumes increasing 22.2% annually.
Capital spending delays threaten fair value of $532.46.
Forecasts may miss recent price-sensitive company announcements.
Bullish Signals
Intuitive Surgical boasts strong long-term performance with a 3-year total shareholder return of 51.04% and a 5-year total shareholder return of 64.51%, indicating sustained compounding value despite recent short-term volatility.
The installed base of da Vinci systems is growing robustly at an annual rate of 15.1%, with procedure volumes increasing by 22.2% year-over-year to approximately 2.2 million procedures performed annually.
Valuation models, such as the Tokyo narrative, peg a fair value of $532.46, suggesting the current share price of roughly $457.78 represents a modest discount and potential upside opportunity.
Intuitive Surgical continues to post steady revenue and net income growth while trading at an intrinsic premium that could magnify future gains if high expectations are met.
Risk Factors
The stock has experienced significant short-term downside, including an 18.54% decline year-to-date and a 2.8% drop over the last 7 days.
Intuitive Surgical trades at a rich P/E ratio of 54.4x, which is substantially higher than the US Medical Equipment industry average of 23.6x and peers' average of 26.1x, creating vulnerability if earnings growth fails to justify the premium.
The valuation depends heavily on procedure volumes growing at 22.2% per year; any slowdown in this growth rate could significantly impact the stock price given the high multiple.
There is a risk that hospitals may delay capital and service spending on existing or new da Vinci systems, which would directly challenge the recurring revenue narrative supporting the fair value of $532.46.
The analysis relies on analyst forecasts and historical data which may not factor in the latest price-sensitive company announcements or recent qualitative material developments.
Shares of Intuitive Surgical (NASDAQ: ISRG) have surged approximately 580% over the past decade, significantly outpacing the S&P 500's 240% gain during the same period. The company, known for its da Vinci surgical robot, operates as an industry pioneer with a substantial installed base of 11,395 systems globally. Despite strong demand and a 17% year-over-year increase in surgeries performed using the robots in the first quarter of 2026—which exceeded the 12% growth in physical unit sales—the article argues that selling the robots themselves is not the primary driver of Intuitive Surgical's immense valuation or cash flow. Instead, only 23% of the company's revenues are derived from direct robot sales, highlighting that investors must look beyond the initial hardware purchase to understand the business model's core mechanics.
The true growth engine for Intuitive Surgical lies in its recurring revenue streams from parts and services. Once a da Vinci system is installed, every surgery performed requires the replacement of instruments and accessories, contributing about 60% to the company's top line. Additionally, servicing needs and other support generate approximately 15% of revenues. This creates an annuity-like effect where each new robot sold expands the potential for future recurring revenue until the system is decommissioned. The more surgeries conducted with da Vinci technology, the higher the volume of consumables needed, and as the scope of procedures supported by the robots grows, so too does the variety of accessories required to perform them.
While Intuitive Surgical maintains a high price-to-earnings ratio of 58x, the article positions it as a powerful cash-generating machine driven by this "parts and services flywheel" rather than one-time hardware sales. The text notes that the company was not included in the Motley Fool Stock Advisor's list of ten best stocks to buy now for 2026, which instead featured companies like Netflix and Nvidia, though it acknowledges the Motley Fool holds positions in Intuitive Surgical and has recommended specific options on the stock. The underlying thesis remains that the long-term investment case depends on the expanding ecosystem of consumables and services attached to the growing installed base of surgical robots.
📈 ISRG shares surged 580% over a decade, vastly outperforming the S&P 500.
🔧 Over 60% of revenue comes from recurring parts, instruments, and accessories sales.
⚡ High volume of surgeries exceeds robot deployments, creating massive future demand.
📈 Intuitive Surgical (ISRG) shares have risen approximately 580% over the past decade, significantly outperforming the S&P 500's 240% growth.
🤖 The company pioneered the surgical robotics market and currently has an installed base of 11,395 da Vinci surgical robots worldwide.
⚡ While robot demand is strong with 431 systems placed in Q1 2026, only 23% of total revenue comes from selling the actual robots.
🔧 The majority of Intuitive Surgical's revenue is generated from parts, instruments, and accessories used during surgery.
📅 Services account for about 15% of the top line, while instruments and accessories comprise a substantial 60%.
🔄 This business model functions like an annuity where selling more robots expands the recurring revenue base from future parts and service needs.
✂️ The volume of surgeries performed increased by 17% in Q1 2026, indicating that demand for procedures exceeds the rate of new robot deployments.
🔧 As robots age and perform more procedures, they require frequent servicing and replacement instruments, driving consistent cash flow.
🏛️ Intuitive Surgical is described as an "Indispensable Monopoly" providing critical technology that competitors like Nvidia rely on indirectly.
💰 The high valuation of the stock reflects a P/E ratio of 58x, suggesting it is primarily suited for aggressive growth investors.
🚫 Despite its strong performance, ISRG was excluded from The Motley Fool's recent top 10 best stocks list released for current buyers.
📉 Comparisons are made to Netflix and Nvidia as past Stock Advisor picks that delivered massive historical returns prior to their inclusion in the index.
⚠️ Investors are advised to look beyond the initial robot sales to understand the true long-term value of the parts and services flywheel.
Bullish Signals
Intuitive Surgical's stock has risen approximately 580% over the past decade, significantly outperforming the S&P 500 which rose only 240% in the same period.
The company has a massive installed base of 11,395 da Vinci surgical robots currently being used around the world.
Demand for the robots is exceptionally strong, with the company placing 431 systems in the first quarter of 2026, up from 367 a year earlier.
The total installed base grew by 12% year over year, driven by robust demand for surgeries performed with da Vinci robots which increased 17% year over year in Q1 2026.
Parts and accessories represent a massive 60% of the company's top line, while services make up around 15%, creating a highly profitable annuity-like business model.
The 'flywheel effect' ensures that as more robots are sold and used, recurring revenue from parts, instruments, and servicing grows indefinitely until the robot reaches end-of-life.
The Motley Fool maintains positions in and recommends Intuitive Surgical, including specific options plays like long January 2028 $520 calls.
Risk Factors
The stock carries a lofty price-to-earnings ratio of 58x, suggesting the market may be pricing in overly aggressive future growth that could prove unsustainable.
Intuitive Surgical was excluded from The Motley Fool Stock Advisor's top 10 stocks for investors to buy now, indicating analysts prefer alternative investment opportunities over ISRG at this time.
The company relies heavily on recurring revenue from parts and accessories (60% of business) and services (15%), which creates a high risk of concentration if surgeons switch to competitors or surgical volume declines.
The article evaluates Intuitive Surgical (NASDAQ: ISRG) and Vertex Pharmaceuticals (NASDAQ: VRTX) as beaten-down healthcare stocks that may offer opportunities for patient investors with approximately $1,000 to deploy. While both companies have delivered strong returns over the last decade, they have recently underperformed due to specific headwinds. Intuitive Surgical faces challenges related to steep tariffs on its medical devices, intensifying competition in the robotic-assisted surgery market from rivals like Medtronic's Hugo system and Johnson & Johnson, and a valuation of 44.3x forward earnings compared to a 16.5x average for the healthcare sector. Despite these concerns, the company continues to show robust financial performance, with growing revenue, expanding gross margins, and a larger installed base driven by its fifth-generation da Vinci system, which creates a wide moat through high switching costs. The analysis suggests that for long-term holders, Intuitive Surgical remains attractive despite being priced for perfection, allowing an investor $1,000 to purchase two shares at approximately $460 each.
Vertex Pharmaceuticals is noted as having suffered a 14% decline over the past year due to its core cystic fibrosis (CF) business maturing and struggles diversifying its portfolio with limited revenue from new launches. However, the company retains strong prospects through the mid-2030s as it maintains patent exclusivity for essential CF medications that patients require indefinitely. Vertex is expanding into new geographic regions and developing therapies for previously ineligible CF patients. Additionally, recent phase 3 results for povetacicept, an investigational medicine for IgA nephropathy (kidney disease), suggest potential approval and future growth, while other late-stage pipeline candidates like inaxaplin for APOL-1 mediated kidney disease could gain approval within three years. Existing non-CF products such as Journavx are also expected to contribute meaningfully to revenue, making the stock an attractive buy on the dip at roughly $425 per share, which would allow for two shares with a $1,000 investment.
The article concludes by recommending against buying Intuitive Surgical right now in favor of other stocks identified by The Motley Fool Stock Advisor analyst team. While Intuitive Surgical is not part of the current top 10 list, the text cites historical examples to illustrate the potential outperformance of Stock Advisor's selections, noting that a $1,000 investment in Netflix on December 17, 2004, would have grown to $504,832 by now, and an investment in Nvidia on April 15, 2005, would have reached $1,223,471. The Stock Advisor's total average return is highlighted at 971%, significantly outperforming the S&P 500's 202% return, suggesting that investors seeking monster returns should consider the latest top 10 list instead of allocating capital to Intuitive Surgical at this time.
📉 Both healthcare giants underperformed recently due to tariffs, competition, and maturity issues.
💰 Intuitive trades at high valuation but offers strong long-term moat and margins.
💊 Vertex provides diversified growth with a mature CF franchise and promising pipeline.
📉 Intuitive Surgical and Vertex Pharmaceuticals have both significantly underperformed the broader market this year despite their strong long-term track records.
⚠️ Intuitive Surgical faces multiple headwinds including steep tariffs on medical devices and increased competition in the robotic-assisted surgery market from Medtronic and Johnson & Johnson.
💰 Valuation concerns are present for Intuitive Surgical, which trades at a forward earnings multiple of 44.3x compared to a healthcare sector average of 16.5x.
📈 Despite challenges, Intuitive Surgical continues to post strong financial results with expanding gross margins and growth driven by its fifth-generation da Vinci system.
🛡️ The company possesses a wide economic moat due to high switching costs and operates in an underpenetrated niche within robotic-assisted surgery.
📉 Vertex Pharmaceuticals shares have dropped 14% over the past year as its core cystic fibrosis business matures while new product launches have faced setbacks.
💊 Vertex's core cystic fibrosis drugs are expected to generate dependable revenue until at least the mid-2030s when patent exclusivity expires.
🌍 Vertex is expanding into new geographic regions and developing therapies for patients currently ineligible for its existing treatments.
🔬 Pipeline highlights include povetacicept for IgA nephropathy, which showed strong phase 3 results earlier this year, and inaxaplin for kidney disease expected to approve within three years.
💼 Vertex shares are trading around $425 each, allowing an investor with $1,000 to purchase a pair of shares for long-term holding.
⚖️ The article suggests Intuitive Surgical may be attractive for long-term investors looking to hold shares for a decade or more despite current valuation issues.
🧠 Vertex is viewed as a great stock to buy on the dip due to its diversified pipeline prospects and mature but profitable cystic fibrosis franchise.
🛒 With $1,000 invested in either company today, an investor can acquire two shares of Intuitive Surgical trading at approximately $460 per share.
🚀 The Motley Fool notes that while both healthcare giants offer opportunities, their recent performance has lagged behind their historical 10-year returns.
⚠️ Investors are reminded that Intuitive Surgical was not included in the Motley Fool Stock Advisor's current top 10 picks for immediate buying recommendations.
Bullish Signals
Intuitive Surgical has continued to post strong financial results in the first quarter, with revenue and earnings growing at a good clip.
Gross margins expanded for Intuitive Surgical in the first quarter, while its installed base grew largely thanks to the fifth generation of its da Vinci system.
Intuitive Surgical possesses a vast addressable market in the underpenetrated robotic-assisted surgery niche and maintains a wide moat from high switching costs.
The company can likely fend off tariff threats through price raises, demonstrating pricing power despite headwinds.
For long-term investors holding shares for a decade or more, Intuitive Surgical remains attractive at approximately $460 per share.
Vertex Pharmaceuticals' core cystic fibrosis business should continue generating dependable revenue until at least the mid-2030s before patent exclusivity expires.
Vertex is expanding into new regions to increase its addressable market and developing therapies to target CF patients ineligible for current treatments.
Vertex recently posted strong phase 3 results for povetacicept, an investigational medicine for IgA nephropathy that seems destined for approval.
The company's pipeline includes other promising candidates like inaxaplin for kidney disease that could earn approval within the next three years.
Vertex's current non-CF products, including Journavx for acute pain, should eventually contribute meaningfully to revenue growth.
Risk Factors
Intuitive Surgical has already significantly underperformed the broader market this year, indicating potential ongoing struggles.
Steep tariffs are affecting Intuitive Surgical's financial results, and any increase or lack of relief could compound negative effects on earnings over time.
Increased competition in the robotic-assisted surgery market is emerging, with Medtronic launching the Hugo system for urologic procedures while Johnson & Johnson plans to enter the space.
Intuitive Surgical is trading at 44.3x forward earnings compared to the healthcare sector's 16.5x average, meaning the stock is priced for perfection despite current headwinds.
Vertex Pharmaceuticals faces a mature core business in cystic fibrosis that is no longer driving significant growth, having lost much of its expansion potential.
Efforts by Vertex Pharmaceuticals to diversify its portfolio have so far resulted in approved medicines generating little revenue, contributing to the stock's 14% decline over the past year.
Vertex Pharmaceuticals' key medicines will only continue generating dependable revenue until the mid-2030s before losing patent exclusivity.
Intuitive Surgical was not included in The Motley Fool Stock Advisor's top 10 list of recommended stocks for investors to buy now.
Intuitive Surgical shareholders have unanimously approved all four proposals at the company's 2026 Annual Meeting of Stockholders, held virtually on April 30, 2026, and elected a slate of 10 directors to serve until the 2027 annual meeting. The approved initiatives included an advisory vote on executive compensation, the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, and the approval of an amendment to the company's 2010 Incentive Award Plan. Gary Loeb, Executive Vice President and Chief Legal and Compliance Officer, confirmed the presence of a quorum based on proxies received among 355,230,371 outstanding shares of common stock as of the March 2, 2026 record date, with preliminary vote reports indicating sufficient votes for each nominee.
CEO David Rosa highlighted the company's robust operational performance and strategic focus on global expansion and technological innovation during his presentation following the meeting. Intuitive Surgical reported 2025 revenue just over $10 billion, representing a 19% total procedure growth, with a global installed base reaching approximately 12,000 systems after the placement of roughly 1,900 new systems in 2025. The company's first quarter of 2026 saw revenue of about $2.77 billion, marking a 23% increase year over year, alongside 17% total procedure growth. Rosa emphasized the broad adoption of the da Vinci 5 platform, rapid growth for the single-port (SP) and Ion platforms, and recent 510(k) clearance for Force Feedback instruments, all underpinned by a multi-year digital and artificial intelligence roadmap.
Management outlined the company's mission through the "Quintuple Aim," which focuses on improving patient outcomes, enhancing patient experience, optimizing care team experiences, lowering total cost of care, and expanding access to minimally invasive surgery globally. Rosa noted that Intuitive's technology has impacted more than 20 million patients in its history, with international procedures rising from about 17% of the total in 2005 to 35% by 2025, a trajectory expected to continue. The board includes Dr. Craig Barratt, Joseph Beery, Lewis Chew, Dr. Gary Guthart, Sreelakshmi Kolli, Dr. Amy Ladd, Keith Leonard, Jami Dover Nachtsheim, Dr. Monica Reed, and David Rosa, with Amal Johnson's tenure ending after 16 years as an exemplary board member who previously chaired the compensation committee. Despite challenges such as dynamic trade conditions, pricing competition in China, government budget pressures in Japan and the U.K., and GLP-1 drug pressure in the bariatric market, the company maintained a world-class customer sentiment with a Net Promoter Score of 76 based on a third-party J.D. Power survey.
💵 Revenue surged to $10 billion+ annually with Q1 2026 up 23%.
🏛️ Shareholders approved all proposals, including re-electing 10 directors and compensation plans.
🤖 da Vinci 5 adoption grew while GLP-1 drugs pressure bariatric surgery demand.
📈 Intuitive Surgical shareholders voted to approve all four proposals at the 2026 Annual Meeting, including the election of 10 directors.
💼 The board slate re-elected for service until the 2027 meeting consists of Dr. Craig Barratt, Joseph Beery, Lewis Chew, Dr. Gary Guthart, Sreelakshmi Kolli, Dr. Amy Ladd, Keith Leonard, Jami Dover Nachtsheim, Dr. Monica Reed, and David Rosa.
💰 Executive compensation packages for named executive officers were approved by advisory vote of the stockholders.
📋 Stockholders ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year ending Dec. 31, 2026.
🔧 The meeting also approved an amendment and restatement of the company's 2010 Incentive Award Plan.
💵 Intuitive Surgical reported full-year 2025 revenue exceeding $10 billion with total procedure growth of 19%.
🤖 CEO David Rosa highlighted strong adoption of the da Vinci 5 system and rapid growth in single-port (SP) and Ion bronchoscopic platforms.
🔬 The company secured 510(k) clearance for Force Feedback instruments as part of its ongoing innovation roadmap.
🌍 Global international exposure grew significantly from 17% of patients treated in 2005 to 35% by 2025.
💊 Revenue for Q1 2026 reached approximately $2.77 billion, representing a 23% year-over-year increase.
⚠️ Management noted challenges including competitive pricing in China and budget pressures in Japan and the U.K.
📉 The company faces continued pressure in the bariatric market in the U.S. and internationally due to GLP-1 drug usage.
⭐ Intuitive's technology has impacted over 20 million patients, with the platform receiving a world-class J.D. Power Net Promoter Score of 76 in 2025.
📄 Gary Loeb stated that final vote results will be reported in a Form 8-K filed with the SEC within four business days.
🤖 The company maintains a multi-year digital and AI roadmap alongside its robotics and advanced vision systems mission.
Bullish Signals
Intuitive Surgical shareholders approved all four proposals at the 2026 Annual Meeting, including the re-election of the full board slate of 10 directors, demonstrating strong confidence in management's leadership.
The company reported robust financial performance with 2025 revenue exceeding $10 billion and Q1 2026 revenue reaching roughly $2.77 billion, representing a 23% year-over-year increase.
Total procedure growth accelerated to 19% in 2025, with Q1 2026 showing a 17% year-over-year increase, driven by broad adoption of the da Vinci 5 platform and rapid growth in SP and Ion segments.
The global installed base expanded significantly during this period, adding roughly 1,900 systems in 2025 to reach approximately 12,000 total systems worldwide.
Management highlighted major technological milestones including the receipt of 510(k) clearance for Force Feedback instruments and a strategic multi-year digital/AI roadmap to drive future innovation.
Customer satisfaction remains at world-class levels with a J.D. Power 2025 Net Promoter Score of 76, significantly above the 70 threshold considered excellent in the industry.
International expansion continues its upward trajectory, with the proportion of patients treated outside the U.S. rising to 35% by 2025 from 17% in 2005.
The company maintains strong scientific and clinical standing, evidenced by over 4,800 cumulative peer-reviewed articles published on its products as of 2025.
Risk Factors
CEO David Rosa explicitly cited external headwinds as significant challenges for the company in 2026, including a dynamic trade environment, increased pricing and competition in China, government budget pressures in Japan and the U.K., and continued pressure in the bariatric market tied to GLP-1 drugs.
The stock is currently experiencing a sell-off, with analysts suggesting it has set up a '30% rebound opportunity,' indicating recent downward momentum and negative sentiment despite strong operating results.
Management emphasized increased R&D for 2026, which could lead to elevated capital expenditures that may pressure near-term profitability margins given the high absolute revenue of over $10 billion.
The company faces ongoing government budget pressures in key international markets like Japan and the U.K., which directly threatens future demand and growth trajectories in those regions.
The provided article text contains no substantive financial information, news content, or data regarding Intuitive Surgical (ISRG). Instead, the text consists entirely of browser error messages indicating that the source website (www.stocktitan.net) could not be reached. The error logs include a timeout message stating "www.stocktitan.net took too long to respond" and an "ERR_CONNECTION_TIMED_OUT" status code.
The page content further details technical troubleshooting suggestions for resolving connectivity issues, such as checking the internet connection, rebooting network devices like routers and modems, allowing the Chromium browser through firewall settings, and disabling any active proxy servers in system network preferences. No details about director Amy L. Ladd's specific trading activity, share transactions, or other insider trading data mentioned in the broken link title are available within the provided text.
🌐 Connection error prevented access to stocktitan.net.
📉 No data available on Director Amy L. Ladd's share sale.
❌ Unable to summarize insider trading activity or financial implications.
The source article could not be accessed due to a connection error with the website stocktitan.net.
No information regarding Director Amy L. Ladd's share sale or Intuitive Surgical (ISRG) was available in the provided content.
Consequently, no factual summary of insider trading activity or financial implications can be generated from this source.
Bullish Signals
This site can't be reached www.stocktitan.net took too long to respond. Try: Checking the connection Checking the proxy and the firewall ERR_CONNECTION_TIMED_OUT Reload Details Check your Internet connection Check any cables and reboot any routers, modems or other network devices you may be using. Allow Chromium to access the network in your firewall or antivirus settings. If it is already listed as a program allowed to access the network, try removing it from the list and adding it again. If you use a proxy server… Go to Applications > System Settings > Network, select the active network, click the Details… button and deselect any proxies that may be selected.
Risk Factors
Technical failure to access the content source (stocktitan.net) prevents verification of Director Amy L. Ladd's insider trading activity details.
The article header indicates a significant sale of 619 Intuitive Surgical (ISRG) shares, which may signal reduced confidence or liquidity concerns from company leadership.
Inability to retrieve specific transaction dates and price points hinders the ability to assess whether this sale was pre-planned or coincidental.
Intuitive Surgical Inc. (ISRG) saw its shares decline by 2.75% to close at $453.83 on Wednesday, a performance that occurred against the backdrop of broader market weakness. The S&P 500 Index fell 0.04% to 7,135.95, while the Dow Jones Industrial Average dropped 0.57% to reach 48,861.81. Despite this overall negative sentiment, the news article highlights that Intuitive Surgical's stock still outperformed its competitors despite registering a loss on the day.
This move marked the company's third consecutive day of losses in equity trading. The data provided for the summary includes specific figures such as the closing price of $453.83 and the percentage drop of 2.75%, noting that the intraday data reflects trades reported through Nasdaq with potential delays of at least 15 minutes or per exchange requirements. Historical and current end-of-day data were sourced from FACTSET, while market support was acknowledged as coming from Dow Jones and FactSet in partnership with Automated Insights for MarketWatch Automation. The report also notes that the content is provided under copyright by MarketWatch, Inc., dated April 29, 2026.
📉 ISRG shares fell 2.75% to $453.83 as the market declined.
⏳ This marks the third consecutive day of losses for Intuitive Surgical stock.
ℹ️ No specific corporate announcements or financial data were reported.
📉 Intuitive Surgical (ISRG) shares fell 2.75% to $453.83 on Wednesday amid a broadly negative trading session.
📊 The wider market also struggled, with the S&P 500 dropping 0.04% and the Dow Jones falling 0.57%.
⏳ This decline marks the third consecutive day of losses for Intuitive Surgical's stock price.
🕒 The article was published on April 29, 2026, at 4:35 p.m. ET.
ℹ️ No specific financial data or corporate announcements regarding ISRG are included in this report.
Bullish Signals
Intuitive Surgical Inc. stock outperformed competitors during a poor trading session, demonstrating resilience in the market.
Shares traded as high as $453.83 before closing the day down only 2.75%.
Risk Factors
Intuitive Surgical Inc. (ISRG) shares slid 2.75% to $453.83, marking the third consecutive day of losses for the stock.
The price decline occurred during a poor trading session across the broader market, suggesting potential sector-wide weakness despite company-specific outperformance in previous periods.
Intuitive Surgical (ISRG) shares declined by 3.3% as investors reacted to renewed scrutiny regarding a recent FDA early alert concerning specific surgical stapler reloads, alongside a broader valuation-driven pullback following the company's recent earnings release. Market participants also appear to be recalibrating their expectations for Intuitive Surgical after the guidance on procedure growth for 2026 was viewed by some as less aggressive than previously priced in. This combination of regulatory attention and adjusted growth outlook has contributed to the downward price movement observed today.
Insider trading activity over the past six months indicates a net selling trend, with stock traded 39 times on the open market all involving sales rather than purchases. In contrast, institutional investors have shown mixed signals recently, with 1,209 adding shares while 919 decreased their positions during the last quarter. Political figures also participated in the trading, as members of Congress executed four trades in the same period, resulting exclusively in purchases. Additionally, award payments totaling $465,600 have been issued to ISRG employees over the past year, contributing to the broader equity dynamics around the stock.
Wall Street sentiment remains cautiously positive despite the recent price dip, with no sell ratings issued and three firms maintaining buy ratings on the stock in recent months. Of the 15 analysts who have provided price targets for ISRG within the last six months, the median target is set at $590.0. These analyst targets suggest that while short-term volatility may be driven by regulatory and growth expectation adjustments, many market watchers continue to assign significant value to the company's long-term prospects, though investors are actively weighing the risks highlighted by the FDA notices.
📉 ISRG shares fell 3.3% due to FDA alerts and revised 2026 growth expectations.
🧠 Insiders sold heavily while Congress members exclusively bought the stock recently.
🤝 Three analysts maintain buy ratings with a median price target of $590.
📉 Intuitive Surgical (ISRG) shares dropped 3.3% today amid renewed investor concern over recent FDA notices and valuation concerns.
⚠️ The FDA issued an early alert regarding certain surgical stapler reloads, reigniting scrutiny on the company's product safety record.
📉 Analysts suggest the price decline reflects a pullback from recent post-earnings gains as expectations for 2026 procedure growth were deemed less aggressive than market pricing.
📤 Insider trading data shows significant net selling pressure, with ISRG insiders making 39 sales versus 0 purchases over the past six months.
🏦 Institutional ownership is mixed, with 1,209 investors increasing their holdings while 919 decreased positions in the most recent quarter.
💼 Approximately $465,600 in stock awards were paid out to executives over the last year.
👥 Members of Congress displayed bullish activity, trading ISRG four times with all trades being purchases and none being sales.
📊 Wall Street sentiment remains cautiously positive, with three firms issuing buy ratings and zero sell ratings on the stock recently.
🎯 Analyst price targets are mixed, with 15 analysts providing a median target of $590.00 over the last six months.
⚖️ Investors are currently recalibrating their outlook as they weigh recent regulatory notices against long-term growth expectations and high valuation levels.
Bullish Signals
Three Wall Street firms have issued buy ratings on Intuitive Surgical ($ISRG) with zero sell ratings.
Fifteen analysts have offered price targets for $ISRG in the last six months, reflecting strong analyst interest.
Members of Congress have traded $ISRG stock 4 times in the past 6 months, all of which were purchases.
A significant number of institutional investors continue to hold the stock, with 1,209 adding shares in the most recent quarter.
Risk Factors
Intuitive Surgical stock fell 3.3% today as investors weighed renewed concerns over a recent FDA early alert involving certain surgical stapler reloads.
The company faces a valuation-driven pullback after its post-earnings surge, with the market recalibrating expectations for its 2026 procedure growth outlook which was viewed as less aggressive than priced in.
$ISRG insiders have been overwhelmingly net sellers, trading the stock 39 times over the past 6 months with zero purchases and all 39 trades being sales.
Institutional investors reduced their positions significantly, with 919 institutional investors decreasing their holdings while only 1,209 added shares in the most recent quarter.
Intuitive Surgical’s first-quarter 2026 results reveal a nuanced international landscape, characterized by strong overall Outside U.S. (OUS) procedure growth but emerging pockets of weakness specifically in China and Japan. In China, management identifies slower tender activity, intensified pricing pressure, and rising competition from domestic manufacturers as key headwinds adversely impacting system placements and near-term growth visibility. This region is viewed as transitioning into a structurally more competitive and lower-margin market due to the inherent volatility of its tender-based procurement system and the growing preference for local products, even though long-term procedure demand remains intact.
Conversely, challenges in Japan are primarily driven by capital constraints within hospital systems that are delaying adoption rather than direct competition. The outlook for Japan appears more constructive with an improving reimbursement environment expected to gradually unlock demand, suggesting its weaknesses are cyclical rather than structural. Outside these two specific markets, international growth remains robust due to expanding clinical adoption, training infrastructure, and broader access to robotic-assisted surgery, reinforcing the view that global demand fundamentals are secure overall.
Regarding financial metrics, Intuitive Surgical’s shares have declined 17.6% year-to-date, outperforming the industry’s 15% decline in terms of loss but remaining under pressure. The company trades at a forward price-to-earnings ratio of 43.35, which is above the current industry average but still lower than its five-year median of 70.45; consequently, it carries a Value Score of D. Analyst consensus estimates for 2026 earnings imply a 15.7% rise from the prior year, and the stock currently holds a Zacks Rank #3 (Hold). The article notes that while DexCom and Glaukos also report international expansion with growth driven by adoption and infrastructure scaling, Intuitive Surgical must navigate a mix of temporary cyclical factors in Japan and structural policy risks in China to ensure international markets remain consistent growth drivers.
🇨🇳 China faces structural headwinds from pricing pressure and local competition.
🇯🇵 Japan offers long-term growth potential as reimbursement outlook improves.
💰 Analysts forecast 2026 earnings to rise 15.7% year-over-year.
⚖ Stock trades at premium P/E with a "Hold" rating due to international uncertainty.
📉 ISRG's international revenue growth is mixed, with strong overall procedure volume but notable headwinds in China and Japan.
🇨🇳 In China, Intuitive Surgical faces structural challenges from slower tenders, pricing pressure, and increasing competition from domestic players.
🇯🇵 Japan presents cyclical challenges due to hospital capital constraints delaying adoption, though an improving reimbursement outlook supports a more constructive long-term view.
🌍 Outside of China and Japan, international markets are experiencing robust growth driven by expanding clinical adoption and training infrastructure.
⚖️ Analysts conclude that ISRG's international weakness is partly temporary (Japan) and partly structural (China), requiring strategic navigation of policy and competition.
📉 ISRG shares have declined 17.6% year-to-date, underperforming the industry average decline of 15%.
📊 The company trades at a forward P/E of 43.35, which is above the current industry average but below its five-year median of 70.45.
💰 Analysts expect Intuitive Surgical's 2026 earnings to rise approximately 15.7% compared to the prior year.
🏷️ The Zacks Rank for ISRG is #3 (Hold), reflecting the uncertainty surrounding its international market expansion.
🤔 Investors must determine if China will transition into a lower-margin, highly competitive market or if demand can offset margin pressure.
Bullish Signals
Outside US procedure growth remains strong.
Japan shows improving reimbursement and future demand.
Global demand outside China and Japan stays intact.
2026 earnings expected to rise 15.7%.
Shares trade at 43.35 forward P/E, below 70.45 five-year median.
Risk Factors
China headwinds slow growth and impact system placements.
Domestic competition threatens margins amid China procurement volatility.
Hospital capital constraints delay Japan adoption and drag growth.
Valuation sits at a forward P/E of 43.35, signaling overvaluation.
Shares down 17.6% despite implied 2026 earnings growth.
Bullish Signals
Despite headwinds in China and Japan, Intuitive Surgical's overall Outside U.S. (OUS) procedure growth remains strong, demonstrating resilience in the core international segment.
In Japan, management highlighted an improving reimbursement environment that could gradually unlock demand and support future procedure growth, suggesting the local weakness is cyclical rather than structural.
Global demand fundamentals remain intact outside of China and Japan, supported by expanding clinical adoption, training infrastructure, and broader access to robotic-assisted surgery.
The Zacks Consensus Estimate for Intuitive Surgical's 2026 earnings implies a 15.7% rise from the year-ago period's level, indicating positive growth expectations.
Although shares have declined 17.6% so far this year, they are trading at a forward price-to-earnings ratio of 43.35, which is lower than its five-year median of 70.45, potentially presenting a valuation opportunity relative to history.
Risk Factors
Intuitive Surgical's China business faces significant headwinds including slower tender activity, intensified pricing pressure, and rising competition from domestic players, which is adversely impacting system placements and growth visibility.
The tender-based procurement system in China inherently introduces volatility, while a growing preference for local manufacturers complicates Intuitive Surgical's positioning and suggests the market may transition to lower margins.
Japan's international weakness stems from capital constraints within hospital systems that are delaying system adoption, creating cyclical but persistent near-term drag on growth.
Intuitive Surgical carries a Value Score of D and trades at a forward P/E of 43.35, which is above the industry average, indicating potential overvaluation relative to peers.
Shares of ISRG have lost 17.6% so far this year, significantly underperforming despite an implied earnings rise of 15.7% for 2026.
Zacks has assigned Intuitive Surgical a Rank #3 (Hold), signaling cautious sentiment compared to strong buy ratings available in the broader market.
Shares of Intuitive Surgical (ISRG) have gained 4% over the past four weeks to close the last trading session at $470.99, presenting analysts with a mean price target estimate of $589 that suggests a potential upside of approximately 25.1%. The consensus figure is derived from 26 short-term price targets with a standard deviation of $63.45, ranging from a low estimate of $440.00 indicating a 6.6% decline to a high target of $750.00 representing a 59.2% surge. While investors often seek the consensus price target, the article notes that empirical research suggests these targets can frequently mislead due to business incentives leading analysts to inflate their projections for companies they cover or wish to associate with.
Despite the limitations of relying solely on price targets, there is significant optimism surrounding Intuitive Surgical's earnings prospects supported by strong agreement among analysts regarding upward EPS estimate revisions. Over the last 30 days, 11 estimates have moved higher compared to only one that went lower, resulting in a 4.3% increase in the Zacks Consensus Estimate. This positive trend is particularly notable as research indicates a strong correlation between trends in earnings estimate revisions and near-term stock price movements. The company currently holds a Zacks Rank #2 (Buy), placing it in the top 20% among more than 4,000 stocks based on four specific factors related to earnings estimates, which serves as an additional indicator of its potential upside.
The article concludes that while investors should treat price targets with skepticism and avoid making decisions based entirely on them due to potential biases, the direction implied by a tight clustering of estimates provides a valid guide for further fundamental research. The upward trajectory of earnings estimates is viewed as a more reliable metric than the absolute price targets themselves. This perspective comes alongside broader market commentary that highlights ISRG's recent performance and its position within the top-ranked stocks, though the text also includes promotional content regarding a separate list of satellite communications firm picks unrelated to Intuitive Surgical.
📈 ISRG shares rose 4% with analysts projecting a $589 short-term target (25.1% upside).
🆙 Positive earnings revisions boosted consensus estimates by 4.3%, reinforcing a Buy rating.
⚠️ Treat analyst price targets as directional guides rather than guaranteed guarantees.
📈 Intuitive Surgical (ISRG) shares closed at $470.99 after gaining 4% over the past four weeks.
🎯 Wall Street analysts calculate a mean short-term price target of $589, implying 25.1% upside potential from current levels.
📊 Analyst estimates range from a low of $440 (6.6% downside) to a high of $750 (59.2% upside).
⚖️ The standard deviation for analyst price targets is $63.45, indicating variability in the short-term consensus.
🛑 Research suggests that price targets often mislead investors due to business incentives between firms and analysts.
📉 Overly optimistic price targets may be set to promote coverage rather than reflect accurate valuations.
🤝 A tight clustering of price targets, like ISRG's standard deviation, signals strong analyst agreement despite potential bias.
📈 EPS estimate revisions have been predominantly positive, with 11 rising and only 1 falling in the last 30 days.
🆙 The Zacks Consensus Estimate for earnings has increased by 4.3% over the same period.
🏆 ISRG currently holds a Zacks Rank #2 (Buy), placing it in the top 20% of nearly 4,000 ranked stocks based on earnings factors.
🔄 Historical data shows a strong correlation between positive earnings estimate revision trends and near-term stock price gains.
⚠️ Investors are cautioned not to rely solely on price targets but should view them as a guide rather than a guarantee.
🔭 The article concludes that while the magnitude of the gain is uncertain, the upward directional bias of targets is valid.
Bullish Signals
Shares of Intuitive Surgical (ISRG) gained 4% over the past four weeks, closing at $470.99.
Wall Street analysts indicate a mean short-term price target of $589, suggesting a potential upside of 25.1% from current levels.
The most optimistic analyst forecasts a 59.2% surge in the stock price to reach $750.00.
A tight clustering of price targets demonstrates strong agreement among analysts regarding the company's upward potential.
There has been increasing optimism among analysts about ISRG's earnings prospects, with the Zacks Consensus Estimate increasing 4.3%.
Eleven estimates have moved higher over the last 30 days while only one has gone lower.
ISRG holds a Zacks Rank #2 (Buy), placing it in the top 20% of more than 4,000 stocks based on earnings estimate factors.
The company boasts an impressive externally-audited track record which supports conclusions about its near-term upside potential.
Risk Factors
Analyst consensus price targets have been historically unreliable, as empirical research indicates they mislead investors more often than they guide actual stock direction.
Many analysts set overly optimistic price targets to drum up interest in companies with which their own firms have business relationships or seek associations, potentially inflating the mean estimate of $589 for ISRG.
Despite a Zacks Rank #2 (Buy) status, the article notes that even high-probability picks have failure rates ('all our elite picks aren't winners'), and references past doubles like Hims & Hers Health as potential anomalies rather than guaranteed benchmarks.
The standard deviation among analyst estimates is $63.45, indicating significant variability in predictions, with the lowest estimate projecting a 6.6% decline from current levels, suggesting downside risk if sentiment shifts.
Intuitive Surgical Inc (NASDAQ: ISRG) has emerged as a notable candidate under a screening strategy that combines fundamental analysis with technical setups to identify high-potential growth stocks. This approach prioritizes companies demonstrating robust revenue and earnings growth alongside solid financial health, while simultaneously seeking specific technical configurations that suggest an impending price breakout. The company, recognized as a pioneer in robotic-assisted surgery using its da Vinci and Ion surgical systems, received a Growth rating of 8 out of 10 and a ChartMill Health rating of 9 out of 10 based on these criteria.
Fundamentally, ISRG has shown impressive expansion with Earnings Per Share increasing by 25.92% over the past year and revenue growing by 20.51% in the same period. The company maintains a pristine financial balance sheet characterized by zero outstanding debt and a Profitability rating of 9 out of 10. Its Altman-Z score stands at 40.00, which is among the highest in the Health Care Equipment & Supplies industry, indicating a near-zero risk of financial distress. These metrics suggest the company is effectively converting growth into profit while retaining the ability to fund expansion without risky leverage.
On the technical side, despite a poor overall rating of 1 out of 10 due to a negative long-term trend and 12-month underperformance relative to the broader market, ISRG presents a compelling opportunity based on its Setup Rating of 8 out of 10. The stock has been consolidating within a range between roughly $448 and $491, currently trading just below a key resistance zone between $477.85 and $483.63, which is reinforced by moving averages and trend lines. A "Pocket Pivot" volume-based accumulation signal suggests institutional buyer interest, and analysts note that a decisive break above the resistance with strong volume could signal a trend reversal. For investors, this setup allows for a favorable risk/reward ratio, with stop-loss orders potentially positioned below the support zone around $453.
Consequently, ISRG is categorized in multiple ChartMill screener lists, including those for fastest growing stocks, revenue growth leaders, and high EPS growth stocks. The article emphasizes that while this combination of strong fundamentals and a clear technical entry point makes the stock a textbook candidate for quality-focused investors, it serves as an informational tool rather than direct investment advice. Past performance is noted not to guarantee future results, and the screening strategy aims to act as a filter that waits for favorable entry points by merging quality indicators with timing mechanics.
🚀 ISRG shows exceptional fundamentals with 25.92% EPS growth and zero debt.
⚖️ Price consolidates near resistance; a breakout could reverse the downtrend.
🛑 Set stop-losses below $453 to manage downside risk effectively.
📈 Intuitive Surgical (ISRG) combines fundamental strength with a promising technical setup, identified by a dual-discipline screening strategy.
💰 The company earned an 8/10 Growth rating, with EPS rising 25.92% and revenue expanding 20.51% over the past year.
🛡️ Financial health is exceptional, highlighted by a 9/10 ChartMill Health rating, zero outstanding debt, and a top-tier Altman-Z score of 40.00.
📊 Profitability remains robust with a 9/10 rating, allowing the firm to fund expansion without risky leverage while converting growth into earnings.
📉 Although the overall technical rating is low (1/10) due to negative long-term trends, the Setup Rating is solid at 8/10.
⚖️ Price has been consolidating between $448 and $491, currently hovering near a key resistance zone between $477.85 and $483.63.
🔁 A breakout above the resistance zone with strong volume could signal a reversal of the recent downtrend.
📈 A "Pocket Pivot" signal indicates volume-based accumulation by institutional buyers, reinforcing the potential for upward movement.
🛑 Investors can risk-manage the trade by setting stop-loss orders below the support zone around $453 to limit downside exposure.
🏥 Strong demand for the da Vinci and Ion surgical systems continues to drive the company's impressive top-line growth metrics.
📱 ChartMill lists ISRG in its fastest growing stocks screen due to high EPS and sales growth performance.
💹 ISRG is also featured on revenue growth leaders and High EPS Growth Stocks screens, confirming its status as a profitable health care leader.
⚠️ The analysis notes that even superior fundamentals are not a sufficient investment if the price or timing is incorrect.
🔍 This screening approach acts as a quality filter that specifically waits for favorable entry points based on technical configurations.
📜 All data and ratings are presented for informational purposes, with a disclaimer advising independent research or financial consultation.
Bullish Signals
Intuitive Surgical earned a Growth rating of 8 out of 10, with Earnings Per Share growing by 25.92% and revenue expanding by 20.51% over the past year.
The company carries no outstanding debt and achieved a ChartMill Health rating of 9 out of 10, supported by an Altman-Z score of 40.00 indicating near-zero risk of financial distress.
ISRG demonstrated strong profitability with a Profitability rating of 9 out of 10, effectively converting its rapid topline growth into real profits.
Technical analysis identifies a Setup Rating of 8 out of 10, suggesting the stock is consolidating near key resistance zones between $477.85 and $483.63 after trading in a range from roughly $448 to $491.
A recent 'Pocket Pivot' signal indicates that institutional buyers are stepping in to accumulate shares, adding weight to a potential price reversal.
The stock qualifies for multiple ChartMill screener lists including 'fastest growing stocks', 'revenue growth leaders', and 'High EPS Growth Stocks', highlighting its status as a market leader.
The risk/reward ratio is currently viewed as favorable, allowing investors to participate in a potential breakout while limiting downside by placing a stop-loss below the support zone around $453.
Risk Factors
The stock carries a poor overall technical rating of 1 out of 10 due to a negative long-term trend and 12-month underperformance relative to the broader market.
The company has been trading in a range between $448 and $491, hovering just below a key resistance zone which suggests limited upside potential until a decisive breakout occurs.
Despite a recent 'Pocket Pivot' signal, the setup relies on investors placing a stop-loss below the support zone around $453, which caps potential gains if the stock does not break out immediately.
The article warns that even strong fundamentals are insufficient if the stock is purchased at the wrong price or time, highlighting valuation risk as a major consideration.
Intuitive Surgical reported first quarter results for fiscal year 2026 that exceeded Wall Street expectations, driven by robust global procedure growth and the expansion of its da Vinci and Ion robotic platforms. CEO David Rosa highlighted a 17% increase in total procedures, attributing this growth to broad-based adoption across both product lines as customers advance minimally invasive care. Notable performance was observed in after-hours and non-urology procedures, alongside increased uptake of the newer da Vinci 5 system, which further boosted overall utilization rates within the installed base.
During the earnings call, analysts focused on several strategic questions that revealed management's direction and market outlook. Travis Steed from Bank of America inquired about the integration of AI and digital infrastructure, prompting CEO Rosa to detail plans for layered AI capabilities centered on clinical value and data-driven differentiation via da Vinci 5. Larry Biegelsen of Wells Fargo sought specifics on appendectomy procedures and reimbursement opportunities in Japan; CFO Jamie Samath responded that while it is too early to quantify market impacts, the company is seeing promising early outcomes with incremental reimbursement for select procedures. Robert Marcus from JPMorgan questioned the limits of system placements driven by utilization growth, leading Samath to note that further gains depend on regional mix and da Vinci 5 adoption without providing specific numbers.
Further questioning highlighted international dynamics and product innovation. Frederick Wise of Stifel asked why international instrument and accessory growth outpaced procedure volumes, which Samath explained as a result of lumpy distributor ordering patterns, stocking behaviors, and foreign exchange impacts. David Roman from Goldman Sachs explored SP platform adoption and international strategy, with management emphasizing continued investment in geographic and procedural clearances alongside a localized approach to market access and pricing. Looking ahead, the StockStory team identifies key signposts including the pace of adoption for new products like Force Feedback instruments and the SP stapler, the impact of evolving reimbursement policies and expanded indications in international markets, and the rollout of digital and AI-enabled features, while monitoring Intuitive Surgical’s ability to sustain innovation-led revenue growth against input cost pressures.
📈 Q1 2026 results beat expectations with a 17% rise in total procedures.
⚙️ Utilization grew via after-hours work and new da Vinci 5 system adoption.
💰 Management faces questions on reimbursement impacts and AI clinical value integration.
📈 Intuitive Surgical reported Q1 2026 results that surpassed Wall Street expectations, driven by a 17% increase in total procedures.
🖤 CEO David Rosa attributed the strong performance to broad-based adoption of both da Vinci and Ion platforms globally.
⚙️ Utilization rates increased notably due to gains in after-hours procedures and uptake of newer systems like da Vinci 5 outside of urology.
🧠 Analyst Travis Steed from Bank of America questioned the role of AI, with management outlining plans for layered AI capabilities focused on clinical value via da Vinci 5's installed base.
💊 Larry Biegelsen of Wells Fargo sought specifics on appendectomy and Japan reimbursement, receiving a response that it is too early to quantify market impact but promising outcomes are emerging.
📉 CFO Jamie Samath noted that further utilization growth depends on regional mix and da Vinci 5 adoption, declining to provide a specific quantity for the opportunity.
🌍 Frederick Wise from Stifel asked why international instrument growth outpaced procedures, which was attributed to lumpy distributor ordering patterns and foreign exchange fluctuations.
🛠️ David Roman of Goldman Sachs inquired about SP platform adoption and international strategy, prompting management to outline continued investment in geographic clearances and a localized market access approach.
📊 Analysts expect future focus on the adoption pace of new products like Force Feedback instruments and the SP stapler.
💰 The company faces ongoing watch regarding the impact of new reimbursement policies and expanded indications in key international markets.
⚡ Key signposts for investors include sustaining innovation-led revenue growth and navigating input cost pressures.
📈 Intuitive Surgical's stock price rose from $451.29 to $472.05 following the earnings release.
📊 This summary covers analyst questions regarding AI, reimbursement, international strategy, and future adoption rates from the Q1 2026 earnings call.
🚀 The article also promotes StockStory's research report on whether ISRG is at an inflection point for buying or selling.
Bullish Signals
Intuitive Surgical's Q1 2026 results exceeded Wall Street expectations, driven by a 17% year-over-year increase in total procedures.
Management highlighted broad-based adoption across both the da Vinci and Ion platforms, with customers advancing minimally invasive care.
The company reported notable gains in after-hours and non-urology procedures, as well as increased uptake of newer systems like the da Vinci 5.
CEO David Rosa detailed plans for layered AI capabilities via da Vinci 5's installed base to drive clinical value and data-driven differentiation.
CFO Jamie Samath flagged promising early outcomes and incremental reimbursement opportunities for select procedures in Japan, despite being too early to quantify total impact.
Management outlined continued investment in geographic and procedural clearances internationally, along with a localized approach to market access and pricing.
Risk Factors
Management declined to quantify future procedure growth opportunities or system placement upside, leaving revenue visibility uncertain beyond current adoption trends.
International instrument and accessory growth outpaced procedures due to lumpy distributor ordering patterns and foreign exchange headwinds, raising questions about the sustainability of top-line velocity.
The pace of adoption for recently launched products, including Force Feedback instruments and the SP stapler, remains a critical signpost that has not yet been validated by strong metrics.
Management indicated it is too early to size market impacts or incremental reimbursement benefits for specific procedures like appendectomies in Japan, signaling significant timing uncertainty.
Company growth depends on navigating ongoing input cost pressures and sustaining innovation-led expansion without clear quantified reserves or margins disclosed.
Intuitive Surgical (ISRG) reported strong Q1 2026 non-GAAP earnings, posting EPS of $2.50 against a consensus of $2.11, while revenue reached $2.77 billion, representing a 23% year-over-year increase. The company successfully placed 431 new da Vinci robotic systems during the quarter, including 232 units of the newer da Vinci 5 platform. This latest generation has expanded the installed base to 1,500 systems and is credited with driving a 4% U.S. utilization growth rate that exceeds that of the prior da Vinci Xi model. The company posted its fourth consecutive earnings beat, supported by a 47.95% jump in operating income and an expansion of gross margins to 67.8%.
Despite these operational strengths, shares of ISRG have declined roughly 15% year-over-year and trade at a 20% discount to their 52-week high of $603.88, hovering around $482.22 as of the latest report on April 21. Analysts from 24/7 Wall St. view this price action as a potential buying opportunity, setting a price target of $615.93 which implies approximately 28% upside over the next 12 months. The bullish case relies heavily on sustained da Vinci 5 adoption, with Bulls projecting a bull-case price of $649.08 if quarterly placements remain above 230 units. Growth is further supported by single-port procedures surging 68% year-over-year and Ion procedure volumes climbing 39%, bolstered by positive clinical data from Mayo Clinic showing a 79% diagnostic yield for lung lesion biopsies.
However, significant headwinds and valuation concerns persist in the bear case. Intuitive Surgical currently trades at a P/E ratio of 58 and an EV/EBITDA multiple of 42, with analysts warning that procedure growth is expected to decelerate from 18% in 2025 to between 13.5% and 15.5% in 2026. Additional risks include approximately 1% revenue drag from tariffs on sourcing from Mexico, Germany, and China, a 10% decline in the bariatrics segment due to GLP-1 adoption, and policy-driven pricing pressure in China. Insider activity has shown net selling, though analysts note this is largely attributable to scheduled vesting rather than lack of confidence. Even under bearish scenarios, the estimated price target remains at $546.67, which is still above current trading levels.
The investment thesis centers on ISRG's status as a high-quality compounder that is trading significantly below its recent highs while maintaining robust revenue growth. The bull case remains intact provided da Vinci 5 placements continue to exceed expectations and the tariff impact stays contained at roughly 1%, though the setup could weaken if procedure growth slips below 13% or if hospital capital expenditure tightens materially. Long-term outlooks for 2027 through 2029 are not explicitly modeled but rely on assumptions of mid-teens procedure growth, modest multiple compression, and ongoing share buybacks to support shareholder returns.
📈 Q1 EPS beat consensus at $2.50 with revenue jumping 23% year-over-year.
🔧 Installed base grew to 431 units, driven by strong da Vinci 5 adoption.
⚠️ Analysts see upside despite valuation concerns and minor tariff headwinds.
📈 Intuitive Surgical (ISRG) reported Q1 2026 non-GAAP EPS of $2.50, beating the $2.11 analyst consensus.
💰 Revenue reached $2.77 billion, representing a 23% year-over-year increase driven by strong adoption of da Vinci systems.
🤖 The company placed 431 new da Vinci systems, including 232 units of the newer da Vinci 5 platform in its installed base.
📉 Shares are currently trading at a 20% discount to their 52-week high following a 15% decline over the last year.
🤲 Analysts recommend ISRG as a buying opportunity, with a price target of $615.93 implying roughly 28% upside.
🔍 da Vinci 5 utilization in the U.S. has grown by 4%, exceeding the performance metrics of the previous Xi generation.
🧬 Advanced procedure types like Single Port surgeries grew 68% year-over-year, bolstered by positive clinical studies.
⚠️ Bearish concerns focus on valuation multiples, with the stock trading at a P/E ratio of 58 and potential deceleration in growth.
🌍 External headwinds include tariffs on components from Mexico, Germany, and China adding approximately 1% revenue drag.
💊 The GLP-1 obesity drug trend has negatively impacted bariatrics procedures, causing a decline in that specific segment of 10%.
📉 Insider activity shows net selling, though analysts suggest this is largely attributable to scheduled stock vesting.
✅ Gross margins expanded to 67.8%, with da Vinci 5 contribution margins becoming comparable to the older Xi model.
🎯 A bull case scenario projects a total return of 34.6% if placements stay above 230 per quarter and tariffs remain stable.
📉 A bear case analysis suggests a lower price target of $546.67, which is still above the current stock price.
🔮 Long-term projections assume mid-teens procedure growth through 2030 alongside modest compression in valuation multiples.
💹 Continued buyback programs and high-quality compounder characteristics support the thesis despite recent volatility.
Bullish Signals
Intuitive Surgical delivered Q1 non-GAAP EPS of $2.50, beating the consensus estimate of $2.11 and marking four straight quarters of EPS beats.
The company placed 431 da Vinci systems in the quarter, with 232 da Vinci 5 units now contributing to a growing installed base of 1,500 systems.
da Vinci 5 adoption is accelerating, driving U.S. utilization growth of 4%, which exceeds the performance of the legacy da Vinci Xi model.
Single Port procedures grew impressively by 68% year-over-year, while Ion procedures climbed 39%, bolstered by a Mayo Clinic study showing 79% diagnostic yield.
Gross margins expanded to 67.8%, and da Vinci 5 contribution margins have become comparable with the older Xi platform, indicating strong operating leverage.
Analysts see Intuitive Surgical trading at a 20% discount to its 52-week high, creating a potential buying opportunity with a price target of $615.93 implying 28% upside.
The stock has shown recent stabilization, gaining 2.77% over the past week following the strong Q1 earnings print on April 21.
Risk Factors
The stock is down 5.1% over the past year and trades 20% below its 52-week high, indicating recent bearish sentiment despite strong quarterly results.
Procedure growth is projected to decelerate from 18% in 2025 to between 13.5% and 15.5% in 2026, raising concerns about slowing top-line expansion.
Tariffs on sourcing from Mexico, Germany, and China are expected to add roughly 1% revenue drag, negatively impacting margins.
The adoption of GLP-1 medications has pulled bariatrics procedures down 10%, creating a specific headwind for that therapeutic area.
China faces policy-driven pricing pressure which could suppress revenue from that market.
Insider activity has shown net selling, although analysts attribute this largely to scheduled vesting rather than lack of confidence.
The setup weakens if procedure growth slips below 13% or if hospital capital expenditure tightens materially.
Future earnings projections are uncertain as international ramp-up for da Vinci 5 and telesurgery commercialization remain key variables.
Zacks Investment Research recommends five robotics stocks for investment in the balance of 2026, including Intuitive Surgical Inc. (ISRG), which carries a Zacks Rank #2 Buy rating alongside Autodesk, Rockwell Automation, Nordson Corp., and Teradyne. The global robotics market is projected to grow significantly due to AI advancements, automation demand, and labor shortage mitigation across manufacturing, healthcare, and logistics. While the sector offers potential for substantial returns by enhancing precision and reducing operational costs, investors face risks including high R&D expenses, regulatory hurdles, and data privacy concerns. Autodesk is highlighted for its successful cloud subscription model and AI-driven innovation in AutoCAD and Revit, which strengthen customer dependency and expand operating margins through generative design and predictive analytics capabilities that justify premium pricing.
🤖 Five robotics stocks recommended for 2026 investment.
💰 All five hold a Zacks Rank #2 Buy rating.
📈 Includes Intuitive Surgical, Autodesk, and Rockwell Automation.
`.
2. **Analyze the Input Content:**
* Title: 5 Stocks to Buy With Extensive Robotics Applications for 2026.
* Source: Zacks Investment Research (via Globe and Mail).
* Date: Tue Apr 28, 8:26AM CDT.
* Topic: Robotics stocks for investment in 2026.
* Specific Company Mentioned: Intuitive Surgical Inc. ISRG is one of the five recommended stocks.
Zacks Investment Research recently identified five robotics stocks recommended for investment through 2026, highlighting Autodesk Inc., Intuitive Surgical Inc., Rockwell Automation Inc., Nordson Corp., and Teradyne Inc., all of which currently carry a Zacks Rank #2. The global robotics market is expected to grow significantly due to innovations in AI, machine learning, and the need to address labor shortages and enhance operational precision. While the sector offers substantial potential returns through efficiency gains and cost reduction, investors must consider associated risks such as high R&D costs, regulatory hurdles, data privacy concerns, and market volatility. Autodesk Inc. is noted for its successful transition to a cloud-based subscription model that ensures predictable recurring revenues and expanding margins, while embedding AI into platforms like AutoCAD and Fusion to drive productivity and strengthen customer retention, with expected revenue and earnings growth rates of 13% and 18.7% respectively for the fiscal year ending January 2027.
Intuitive Surgical Inc., known for its da Vinci robotic systems, is integrating AI and digital tools such as Case Insights into its ecosystem to link surgical data with clinical outcomes, providing training value and real-time decision support. The company is also piloting Intuitive Telepresence for remote surgical support, which aims to deepen its clinical moat as it scales commercial workflows and adjusts to regulatory changes, projecting a 16.2% revenue growth rate and 15.7% earnings growth rate for the current fiscal year. Rockwell Automation Inc. is positioned to benefit from productivity-focused investments across end markets including life sciences and mining, with recent acquisitions expected to boost performance despite challenges like elevated costs and supply-chain issues, alongside portfolio optimization and pricing actions that support an expected revenue growth of 6% and earnings growth of 15.3% for the year ending September 2026.
Nordson Corp. is experiencing steady demand in medical components and engineered fluid solutions, with its Advanced Technology Solutions segment supported by strength in semiconductor-related electronics dispense and x-ray systems. The Industrial Precision Solutions segment has returned to modest organic growth following stabilization in demand for polymer processing and automotive applications, though the specific quantitative targets for full-year sales and earnings improvements were cut off in the source text. These five companies represent a mix of software, healthcare robotics, industrial automation, and precision manufacturing solutions, each leveraging AI and autonomous capabilities to expand their market presence and revenue streams as the industry matures.
🤖 Robotics sector shows strong potential driven by AI, automation, and market expansion.
⚠️ Investors face risks from high R&D costs, regulations, and data privacy issues.
📋 Zacks ranks five robotics stocks as "Buy," highlighting Autodesk and Intuitive Surgical.
🏭 Top firms like Rockwell expect double-digit revenue and earnings growth through 2026.
🤖 Robotics companies are driving efficiency in manufacturing, healthcare, and logistics, with the global market poised for significant growth fueled by AI and automation.
⚠️ Investors face risks in the robotics space, including high R&D costs, regulatory challenges, data privacy concerns, and societal impacts of automation.
📋 Zacks Investment Research recommends five robotics stocks with a "Buy" (Rank #2) rating for investment through 2026.
💻 Autodesk (ADSK) benefits from a cloud subscription model, strong cash flow, and AI-driven innovation across AutoCAD, Revit, and Fusion platforms.
📈 Autodesk is expected to grow revenue by 13% and earnings by 18.7% for the current year ending January 2027.
🏥 Intuitive Surgical (ISRG) is embedding AI into its robotic ecosystem via Case Insights, which provides objective performance metrics for surgeons.
📞 ISRG is piloting telecollaboration through Intuitive Telepresence to support remote surgical education and scaling digital features in healthcare.
💉 Intuitive Surgical expects revenue growth of 16.2% and earnings growth of 15.7% for the current year with improved analyst estimates.
🏭 Rockwell Automation (ROK) is focusing on productivity through automation investments across life sciences, food & beverage, mining, and other end markets.
📉 Recent acquisitions and portfolio optimizations at Rockwell are expected to drive growth despite manufacturing contraction and cost headwinds.
⚙️ Rockwell Automation anticipates revenue growth of 6% and earnings growth of 15.3% for the year ending September 2026.
🔬 Nordson (NDSN) is benefiting from steady demand in medical components and engineered fluid solutions, particularly in semiconductor electronics dispense.
📈 The Industrial Precision Solutions segment at Nordson has returned to modest organic growth as automotive and polymer processing demand stabilizes.
Bullish Signals
Intuitive Surgical is embedding AI and digital tools into its robotic ecosystem, with Case Insights integrated into da Vinci 5 providing objective performance indicators that link to improved clinical outcomes like reduced hospital stays.
ISRG is piloting Intuitive Telepresence for remote surgical support and education, positioning itself as a leader in broader AI-driven healthcare transformation.
The Zacks Consensus Estimate for ISRG's current year earnings has improved by 3.7% over the last seven days, signaling growing analyst confidence.
ISRG is expected to post revenue and earnings growth rates of 16.2% and 15.7%, respectively, for the current year.
Rockwell Automation is benefiting from investments across many end markets that will support growth despite cost headwinds, supply-chain issues, and a challenging contraction in manufacturing activity.
ROK's optimization efforts and price increase actions are expected to drive growth and negate negative market factors, while recent acquisitions will further boost performance.
Rockwell Automation is expected to deliver an earnings growth rate of 15.3% for the current year ending September 2026.
Nordson is seeing steady demand in medical components, with its Advanced Technology Solutions segment being lifted by strength in semiconductor-related electronics dispense and x-ray system product lines.
Risk Factors
The article explicitly warns that robotics technology is still evolving, posing inherent risks of high R&D costs with no guaranteed success.
Broader industry risks mentioned include regulatory challenges, market volatility, concerns about job displacement, and data privacy issues.
Intuitive Surgical's new AI features like Case Insights and Telepresence represent early-stage pilots that face potential delays or require additional regulatory adjustments before full commercial scaling.
Rockwell Automation must successfully navigate headwinds from elevated costs and a challenging contraction in manufacturing activity to realize its growth targets.
The article notes that only 0.1% of Rockwell Automation's earnings estimate improved over the last 30 days, suggesting relatively weak analyst momentum compared to peers.
Nordson's recent business performance is described as merely returning to 'modest organic growth,' implying a lack of significant upside momentum in key segments.
Intuitive Surgical, Inc. (ISRG) is highlighted by Zacks Investment Research as a compelling growth stock within the Zacks Growth Style Score system. The article notes that while growth stocks inherently carry higher risk and volatility, ISRG currently possesses a favorable Growth Score of B and a top Zacks Rank #2 (Buy). Research indicates that stocks combining a Growth Score of A or B with a Zacks Rank of #1 or #2 have historically delivered superior returns, making ISRG a potential market outperformer for investors seeking cutting-edge growth opportunities.
The primary drivers for this recommendation include robust earnings growth and strong cash flow generation. While the company's historical earnings per share (EPS) growth rate stands at 13.8%, the projected EPS growth for the current year is estimated at 12.4%, significantly exceeding the industry average of 10.6%. Additionally, ISRG demonstrates superior cash flow capabilities with a year-over-year growth rate of 15.8%, which far surpasses the industry average of 0.8% and supports future projects without needing expensive external funding. The company has also maintained an annualized cash flow growth rate of 19.5% over the past three to five years compared to the industry average of 6.9%.
Further validation of the stock's momentum is found in earnings estimate revisions, which show a positive trend favorable for near-term price movements. Over the past month alone, the Zacks Consensus Estimate for ISRG has increased by 0.6%, reinforcing its status as a strong Buy based on the proprietary system. This combination of high projected earnings growth, exceptional cash flow accumulation, and upward analyst revisions positions Intuitive Surgical as a solid choice for growth-focused investors seeking stocks with strong real growth prospects rather than traditional metrics alone.
📈 Intuitive Surgical ranked top growth stock with favorable Zacks Rank score.
💰 EPS projected to grow 12.4%, exceeding industry average of 10.6%.
💸 Year-over-year cash flow up 15.8%, surpassing peers at 0.8% growth.
📈 Annualized cash flow grew 19.5% over 3-5 years versus 6.9% industry.
📈 Intuitive Surgical (ISRG) is highlighted as a top growth stock by the Zacks Growth Style Score, featuring a favorable score and top Zacks Rank.
💰 The company's earnings per share (EPS) is projected to grow 12.4% this year, significantly outpacing the industry average of 10.6%.
📉 Historical EPS growth for ISRG stands at 13.8%, demonstrating a consistent track record of above-average profit expansion.
💸 Year-over-year cash flow growth is currently 15.8%, which surpasses both many peers and the industry average of 0.8%.
📈 The company's annualized cash flow growth rate has been 19.5% over the past 3-5 years compared to an industry average of 6.9%.
🔄 Upward revisions in earnings estimates have increased the Zacks Consensus Estimate by 0.6% over the past month.
✅ These positive financial trends support a Growth Score of B and solidify ISRG's status as a potential market outperformer for growth investors.
Bullish Signals
Intuitive Surgical holds a top Zacks Rank #2 and favorable Growth Score.
EPS expected to grow 12.4% this year, beating industry average of 10.6%.
Cash flow grew 15.8% YoY, vastly outperforming the industry average of 0.8%.
3-5 year annualized cash flow growth reached 19.5%, versus 6.9% industry average.
Earnings estimates surged 0.6% in past month, showing strong positive momentum.
Risk Factors
Growth stocks carry above-average risk; betting on over-stories can cause large losses.
Intuitive Surgical has a Zacks Rank of 2, not top-tier Strong Buy status.
Bullish Signals
Intuitive Surgical has earned a favorable Growth Score and a top Zacks Rank, placing it on the list of cutting-edge growth stocks recommended by the proprietary system.
The company's EPS is expected to grow 12.4% this year, which crushes the industry average of 10.6%, indicating strong prospects for stock price gains.
Intuitive Surgical's year-over-year cash flow growth of 15.8% significantly outperforms the industry average of 0.8%, providing ample resources to fund new projects without raising expensive outside funds.
The company has achieved a historically superior annualized cash flow growth rate of 19.5% over the past 3-5 years compared to the industry average of 6.9%.
Positive momentum is evident with upward revisions in current-year earnings estimates, where the Zacks Consensus Estimate has surged 0.6% over the past month.
This combination of a Growth Score of B and a Zacks Rank #2 (Buy) indicates that Intuitive Surgical is a potential outperformer and a solid choice for growth investors.
Risk Factors
The article acknowledges that growth stocks usually carry above-average risk and volatility, noting that betting on a stock where the growth story is over could lead to significant loss.
Intuitive Surgical only carries a Zacks Rank of 2 (Buy) rather than a Zacks Rank #1 (Strong Buy), suggesting it may not be in the top tier of current recommendations despite its favorable Growth Score of B.
The stock price of Intuitive Surgical Inc., ticker ISRG (NASDAQ), is currently trading at 470.99 USD, reflecting a decline of 2.33% in the most recent session. Over the past year, the share price has decreased by 11.04%, though it has gained 4.05% over the last month. The company appears on several ChartMill screener lists, including those for fastest growing stocks, revenue growth leaders, and highest analyst upside. Conversely, ChartMill assigns a low technical rating of 1 out of 10 to the stock, indicating that 79.25% of all stocks are performing better than ISRG in terms of yearly performance.
From a fundamental perspective, ISRG holds a strong rating of 7 out of 10 and is recognized for outstanding health and profitability within its industry. Analysts have analyzed the company with an average price target of 615.86 USD, implying an expected price increase of 30.76% over the current market value. On April 20, 2026, Intuitive Surgical reported an earnings per share (EPS) of 2.5 and revenue of 2.77 billion, surpassing analyst expectations by 16.77% and 3.89%, respectively. For the upcoming year, analysts forecast EPS growth of 14.43% and revenue growth of 15.78%.
Intuitive Surgical Inc., headquartered in Sunnyvale, California with approximately 17,021 full-time employees, was founded as a public company through its initial public offering on June 13, 2000. The firm specializes in robotic-assisted surgical solutions and invasive care, offering a comprehensive ecosystem of products including the da Vinci surgical systems for various specialties and the Ion endoluminal system for minimally invasive biopsies. Over the trailing twelve months, the company reported a non-GAAP EPS of 9.62, which represents a 25.92% increase compared to the previous year. The stock currently has a price-to-earnings ratio of 48.96 and does not pay a dividend.
📉 ISRG stock fell 2.33% recently but gained 4.05% over the past month.
📈 Analysts rate fundamentals at 7/10 with a $615.86 price target, implying ~31% upside.
💎 Earnings beat estimates significantly with EPS growth of 14.43% forecasted for next year.
⚠ Technical analysis gives a low 1/10 rating due to underperformance this year.
🏢 Company specializes in robotic surgery systems and trades at a PE ratio of 48.96.
📉 Intuitive Surgical Inc. (ISRG) stock closed at $470.99, reflecting a 2.33% decline in the most recent trading session.
📈 Despite the daily drop, ISRG has gained 4.05% over the past month while declining 11.04% over the last year.
🚀 ChartMill identifies ISRG as part of several top-performing screens, including fastest growing stocks and revenue growth leaders.
⚠️ Technical analysis gives ISRG a low rating of 1 out of 10 due to its underperformance relative to the broader market this year.
💎 Fundamental analysis rates ISRG highly at 7 out of 10, reflecting its strong health and profitability within the healthcare industry.
📅 On April 20, 2026, the company reported earnings that beat analyst expectations by 16.77% for EPS and 3.89% for revenue.
🎯 With 41 analysts covering the stock, the consensus price target stands at $615.86, implying potential upside of roughly 30.76%.
📊 Analysts forecast an EPS growth of 14.43% and revenue growth of 15.78% for the upcoming year.
💹 The company currently trades at a price-to-earnings (PE) ratio of 48.96 based on non-GAAP earnings per share of $9.62.
📉 ISRG has not reported any dividend payments to shareholders, relying instead on capital appreciation and growth prospects.
🤖 The firm specializes in robotic-assisted surgical solutions, with its flagship da Vinci system used for various surgical specialties.
🔬 Intuitive Surgical also utilizes the Ion endoluminal system for minimally invasive diagnostics and lung biopsies.
🏢 Headquartered in Sunnyvale, California, the company employs 17,021 full-time staff and has been publicly listed since 2000.
⚠️ Investors should consult the Technical and Fundamental Analysis tabs for deeper insights into investment suitability.
💼 Full profile data is restricted to registered users who can view more detailed charts and competitor comparisons.
Bullish Signals
ISRG appears on multiple growth stock screens for revenue and upside potential.
April 20 EPS beat expectations by 16.77% with $2.50 reported earnings.
Revenue of $2.77B exceeded estimates by 3.89%.
Analysts target $615.86, suggesting 30.76% upside from current price.
Non-GAAP EPS grew 25.92% in the last twelve months to $9.62.
Future growth projected at 14.43% EPS and 15.78% revenue annually.
Company holds a fundamental score of 7 out of 10 for health and profitability.
ISRG employs 17,021 staff with da Vinci and Ion robotic systems.
Risk Factors
Stock down -2.33% today with short-term weakness.
No dividends paid to shareholders.
Technical rating of 1/10 vs 79.25% of peers performing better.
PE ratio at 48.96 may indicate overvaluation.
Stock down -11.04% over past year.
Analyst target implies 30.76% upside, which is aggressive.
Bullish Signals
ISRG is included in multiple ChartMill growth screens, including fastest growing stocks, revenue growth leaders, and highest analyst upside stock lists.
On April 20, 2026, ISRG beat EPS expectations by 16.77% and beat revenue expectations by 3.89% with reported EPS of $2.50 and revenue of $2.77 billion.
Analysts are projecting an average price target of $615.86 USD, implying a potential 30.76% upside from the current price of $470.99.
Over the last twelve months, non-GAAP EPS grew by 25.92% compared to the previous year with a trailing EPS of $9.62.
Analysts expect strong future growth with projected EPS growth of 14.43% and revenue growth of 15.78% for the coming year.
ISRG maintains an outstanding health and profitability rating in its fundamental assessment, scoring a 7 out of 10 on ChartMill fundamentals.
The company employs 17,021 full-time employees and operates a comprehensive ecosystem of robotic-assisted surgical solutions including the da Vinci and Ion systems.
The company has not paid a dividend to shareholders.
ChartMill assigns a low technical rating of 1 out of 10, indicating weak technical performance compared to the broader market where 79.25% of stocks are performing better.
The PE ratio stands at 48.96, which is relatively high and may be overvalued relative to earnings.
Over the past year, ISRG's stock price has decreased by -11.04%, demonstrating a notable annual decline despite appearing in multiple positive growth screens.
Analyst average price target of 615.86 USD implies a required 30.76% increase to reach targets, which is aggressive and may not materialize if market sentiment worsens.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)